Invention Grant
US07731964B2 Antibodies specific for phosphorylated insulin receptor substrate-1/2 (Ser1101/Ser1149) and uses thereof
有权
磷酸化胰岛素受体底物-1 / 2（Ser1101 / Ser1149）特异性抗体及其用途
- Patent Title: Antibodies specific for phosphorylated insulin receptor substrate-1/2 (Ser1101/Ser1149) and uses thereof
- Patent Title (中): 磷酸化胰岛素受体底物-1 / 2（Ser1101 / Ser1149）特异性抗体及其用途
-
Application No.: US10694874Application Date: 2003-10-28
-
Publication No.: US07731964B2Publication Date: 2010-06-08
- Inventor: Roberto Polakiewicz , Jiong Wu , Yu Li
- Applicant: Roberto Polakiewicz , Jiong Wu , Yu Li
- Applicant Address: US MA Danvers
- Assignee: Cell Signaling Technology, Inc.
- Current Assignee: Cell Signaling Technology, Inc.
- Current Assignee Address: US MA Danvers
- Agency: CST Legal Dept.
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/00
Abstract:
The invention discloses newly-discovered phosphorylation sites in human IRS-1 and IRS-2, serine 1101 (Ser1101) and serine 1149 (Ser1149) respectively, and provides antibodies, both polyclonal and monoclonal, that selectively bind to IRS-1 and/or IRS-2 when phosphorylated at these respective sites, but do not bind to IRS-1 and/or IRS-2 when not phosphorylated at these respective sites. The sites are relevant to insulin-resistance in type 2 diabetes. Also provided are methods for determining the phosphorylation of IRS-1/2 or activity of PKC theta in a biological sample, by using a detectable reagent, such as the disclosed antibodies, that binds to IRS-1/2 only when phosphorylated at Ser1101/Ser1149. Kits comprising the phosphor-IRS-1/2 (Ser1101/1149) antibodies of the invention are also provided.
Public/Granted literature
- US20040097713A1 Antibodies specific for phosphorylated insulin receptor substrate-1/2 (Ser1101/Ser1149) and uses thereof Public/Granted day:2004-05-20
Information query
